FDA Approves New Targeted Drug Showing Major Survival Benefit in Advanced Pancreatic Cancer
August 27, 2026
The U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a new targeted medicine developed by Revolution Medicines for adults with metastatic pancreatic adenocarcinoma, offering a new treatment option for patients facing one of the most difficult forms of cancer to treat.
The approval, announced on August 26, follows results from a late-stage clinical study in which the experimental treatment produced a substantial improvement in survival compared with standard chemotherapy.
Trial Shows Significant Survival Improvement
The FDA’s decision was supported by the RASolute 302 trial, a randomized study involving 500 adults whose metastatic pancreatic cancer had progressed after one previous line of systemic treatment.
Patients were assigned to receive either daraxonrasib or a physician-selected standard chemotherapy regimen. The results showed that patients receiving the new drug had a median overall survival of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy.
That represents an improvement of roughly 6.5 months in median survival. The FDA also reported statistically significant improvements in progression-free survival and overall response rates.
How Rasonque Works
Daraxonrasib belongs to a class of medicines designed to target the RAS family of proteins, which play an important role in controlling cell growth. Changes involving RAS are particularly common in pancreatic tumors.
Rasonque is taken as an oral tablet once a day. The FDA-approved dose is 300 milligrams daily, with treatment continuing until the disease progresses or side effects become unacceptable.
Who Can Receive the Treatment?
The FDA approved Rasonque for adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic treatment or who are not candidates for combination systemic chemotherapy.
Pancreatic adenocarcinoma is the most common form of pancreatic cancer. The disease is particularly challenging because it is frequently detected at an advanced stage and has historically had limited treatment options.
Other Benefits Seen in the Trial
The study showed benefits beyond overall survival.
Median progression-free survival reached 7.2 months for patients receiving daraxonrasib, compared with 3.6 months among those given standard chemotherapy. The objective response rate was 30% with the new drug versus 11% with chemotherapy.
These results suggest that the treatment not only helped patients live longer on average but also delayed disease progression and produced tumor responses in a greater proportion of participants.
FDA Uses Expedited Review Pathways
The FDA moved the application through several programs intended to speed the development and review of treatments for serious diseases.
Daraxonrasib received Breakthrough Therapy and Orphan Drug designations and was granted Priority Review. The agency said the application was approved approximately 6.5 months ahead of its target date.
Before the full approval, the FDA had also allowed Revolution Medicines to establish an expanded-access program for certain patients with previously treated metastatic pancreatic cancer.
Treatment Comes With Potential Risks
Despite the encouraging trial results, Rasonque is not free of side effects. The FDA lists rash, diarrhea, inflammation of the mouth, nausea, fatigue, vomiting, abdominal pain, swelling, reduced appetite and bleeding among the commonly reported adverse effects.
The prescribing information also contains warnings concerning skin and soft-tissue toxicity, oral disorders, gastrointestinal perforation, interstitial lung disease or pneumonitis, and potential harm to an unborn child.
A New Option for a Difficult Cancer
The approval gives doctors another option for patients with metastatic pancreatic adenocarcinoma after previous treatment or for those unable to receive multi-drug chemotherapy.
While the clinical results represent a significant improvement over the chemotherapy comparison used in the trial, the survival figures are median values, meaning individual patient outcomes can vary considerably.
The FDA’s approval nevertheless marks an important development in pancreatic cancer treatment, particularly because the new oral therapy demonstrated a substantial survival advantage in a large randomized clinical trial.
